Treatment
Pembrolizumab and Lenvatinib clinical trials
We’re tracking 30 recruiting studies that include Pembrolizumab and Lenvatinib, each written for real people, not researchers, below.
Recruiting studies
- NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT03486873RecruitingPhase 3
Study extension for people on pembrolizumab, testing long-term safety
This trial follows people with advanced tumors who are already on pembrolizumab (or similar treatment) to check long-term safety and effectiveness. It may help your care team by monitoring benefits and side effects over a longer period.
Tucson, ArizonaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT06364631RecruitingPhase 3
Testing a new approach for advanced kidney cancer
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
ViennaAges 18 years+ - NCT05327686RecruitingPhase 2
Adding focused radiation to immunotherapy for kidney cancer
This Phase 2 trial studies whether adding focused, high-precision radiation to immunotherapy helps people with advanced kidney cancer (that cannot be removed by surgery or has spread). It aims to improve cancer control by combining two treatment approaches.
Birmingham, AlabamaAges 18 years+ - NCT07383441RecruitingPhase 3
Adding Biotherapy or Placebo to Standard Kidney Cancer Treatment
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
Fayetteville, ArkansasAges 18 years+
Common questions
- Are there clinical trials studying Pembrolizumab and Lenvatinib?
- Yes. Clin2 currently lists 30 recruiting studies that include Pembrolizumab and Lenvatinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pembrolizumab and Lenvatinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pembrolizumab and Lenvatinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pembrolizumab and Lenvatinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.